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Summary statement:  We reviewed 33 eyes of 22 patients with refractory diabetic 
macular edema, treated with an average of six 0.3 mg intravitreal ranibizumab injections 
over 48 weeks. Mean visual acuity and central subfield thickness showed statistically 
significant linear trends in improvement with respect to days of follow up. 
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Abstract 
Purpose: 
Diabetic macular edema (DME) can be refractory to multiple treatment modalities. 
Although there have been anecdotal reports of ranibizumab showing efficacy when other 
modalities provided limited benefit, there has been little published on treatment for 
refractory DME. This study sought to investigate this observation further.  
Methods: 
Retrospective chart review.  
Results: 
33 eyes of 22 patients with refractory DME were treated with 0.3 mg intravitreal 
ranibizumab. This group of eyes received an average of 5.1 prior treatments (macular 
laser, intravitreal bevacizumab, triamcinolone acetonide, or dexamethasone implant). The 
mean best corrected visual acuity (BCVA) prior to the initial ranibizumab injection was 
20/110 and the mean central subfield thickness (CSFT) was 384 μm. After 7 visits over 
an average of 48 weeks, during which an average of 6 ranibizumab injections were 
administered, the mean VA improved to 20/90 and the mean CSFT improved to 335 μm. 
Both CSFT and BCVA improved with number of days of follow up in a statistically 
significant fashion (P<0.01). Similarly, both CSFT and VA improved with number of 
ranibizumab injections in a linear fashion, but this was not statistically significant.  
Conclusion 
Ranibizumab can improve DME refractory to prior treatments of laser photocoagulation, 
intravitreal triamcinolone acetonide, and bevacizumab.  
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Introduction 
 Diabetic macular edema (DME) can be refractory to multiple treatment 
modalities.  The literature on the treatment of refractory DME is limited. There have been 
anecdotal reports of intravitreal ranibizumab showing efficacy when other treatment 
modalities provide limited benefit. This study sought to investigate this observation 
further through a retrospective chart review in DME patients refractory to multiple prior 
treatments, who were treated with 0.3 mg intravitreal ranibizumab.   
 
Methods 
This retrospective, uncontrolled chart review studied consecutive patients 
diagnosed with refractory DME who were treated with their first intravitreal ranibizumab 
injections from November 2012 through December 2013.  This project was reviewed by 
Indiana University’s IRB and considered exempt. Refractory DME was diagnosed if the 
patients showed persistent DME of at least 6 months duration despite at least 2 prior 
treatments, including any combination of macular laser photocoagulation, intravitreal 
triamcinolone acetonide, intravitreal bevacizumab, or intravitreal dexamethasone implant.  
Only patients diagnosed with diabetes and using either an oral antihyperglycemic agent 
or insulin were included. 
Exclusion criteria included other causes of macular edema, such as venous 
occlusion or age-related macular degeneration.  Patients were excluded if the baseline 
best corrected visual acuity (BCVA) was better than 20/40 or the central subfield 
thickness (CSFT) on spectral domain optical coherence tomography (OCT) was less than 
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300 microns. A minimum of 6 months of follow-up was required to be eligible for the 
study.  
Patient charts were reviewed for eligibility, and data were extracted regarding the 
patient’s age, gender, previous interventions, and OCT CSFT.  The BCVA, CSFT, 
treatment dates from the initial visit and follow-up visits were recorded.  Snellen visual 
acuity was converted to logMAR visual acuity (logMAR VA) for statistically analysis.  
In cases of missing data points, the last observation was carried forward. Regression 
analysis was performed on the individual data to determine correlations between the 
independent variables of number of days follow-up or number of ranibizumab injections 
and the dependent variables of logMAR VA or CSFT.  Mean values for LogMAR VA 
and CSFT, as well as standard deviations and range, were calculated at each follow up 
visit. Fluorescein angiography was performed on each patient at their initial presentation 
to the clinic; eyes with macular ischemia (foveal avascular zone > 1 disk area) were 
excluded from the study. 
On all visits, response to treatment was evaluated subjectively by Snellen visual 
acuity with best correction, and objectively by biomicroscopic examination and Zeiss 
Cirrus spectral domain OCT (Carl Zeiss Meditec, Jena, Germany).  In all cases, the use of 
ranibizumab and its potential risks and benefits were discussed with the patients before 
signing an informed consent. Ranibizumab 0.3 mg was injected 3.5-4mm posterior to the 
limbus under aseptic conditions.  Patients were assessed every 6 weeks on average.  
Subsequent injections were administered for persistent macular edema on OCT. 
 
Results: 
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The study included 33 eyes of 22 patients with refractory DME. The patient 
demographic and baseline characteristics are summarized in Table 1.  Follow up after 
treatment with ranibizumab ranged from 200 to 622 days; data was analyzed up to the 
seventh visit at a mean of 338 days, and any missing data was carried forward. In 4 
patients the left eye was affected and in 7 the right eye was affected. 11patients had 
bilateral involvement.  All patients had DME for a least 6 months duration prior to 
undergoing ranibizumab treatment.  Prior to treatment with ranibizumab, this group of 
eyes received an average of 5.6 +/- 2.9 prior treatments (33 eyes received 2-14 treatments 
including macular laser, intravitreal bevacizumab, triamcinolone acetonide or 
dexamethasone implant).  Specifically, these 33 eyes received an average of 1.7 +/- 1.4 
macular laser treatments (27 eyes received 1-6 treatments), 0.4 +/- 0.8 intravitreal 
triamcinolone acetonide (9 eyes received 1-3 treatments), 3.4+/- 1.7 bevacizumab (33 
eyes received 1-6 treatments). Both eyes of one patient received 2 prior dexamethasone 
implants.  Macular laser treatment was performed using a modified ETDRS protocol in 
which all leaking microaneuryms were directly treated to achieve a mild gray-white burn, 
followed by grid treatment to areas with diffuse leakage, between 500 and 3000 microns 
from the fovea;  532 nm laser was set to spot size of 50 microns at 0.05 to 0.1 sec.  The 
mean time period between the prior treatment and the initial ranibizumab injection was 
167 days (range 29 - 455 days).  The previous treatments are summarized in Table 2. 
The mean BCVA prior to the initial ranibizumab injection was 20/110 (logMAR 
0.52 +/- 0.38) and the mean CSFT was 384 +/- 129 μm.  After 7 visits over an average of 
48 weeks, during which an average of 6 ranibizumab injections were administered, the 
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mean VA improved to 20/90 (logMAR 0.44 +/- 0.40) and the mean CSFT improved to 
335 +/- 164 μm.  These data are summarized in Table 3. 
Both CSFT and BCVA improved with number of days of follow up in a 
statistically significant fashion (P<0.01).  Similarly, both CSFT and BCVA improved 
with number of ranibizumab injections, but this was not statistically significant.  There 
was a linear trend in improvement of mean CSFT compared to mean number of days of 
follow-up (R² = 0.51), mean CSFT compared to mean number of ranibizumab injections 
(R² = 0.52), mean logMAR VA compared to mean number days of follow-up (R² = 0.74), 
and mean logMAR VA compared to mean number of ranibizumab injections (R² = 0.74).  
These data are presented graphically Figure 1.There were no cases of endophthalmitis, 
retinal detachment, arteriothrombotic events, or death throughout the study period. 
 
Discussion 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have 
become first line therapy in diabetic macular edema (DME) patients, as several recent 
clinical trials suggest that these therapies are more effective than laser photocoagulation 
for DME.1-5 Intravitreal bevacizumab has been used off-label for the treatment DME for a 
number of years.  In 2012, intravitreal ranibizumab was approved by the FDA for DME, 
based on Genentech’s Phase III trials, RIDE and RISE.6,7   
More recently, there has been interest in intravitreal corticosteroids, as the 
dexamethasone implant8 and the fluocinolone implant9,10 have been approved for the 
treatment of DME in 2014 and 2015, respectively.  There are few large prospective 
clinical trials comparing anti-VEGF agents to corticosteroids; DRCR protocol I compared 
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0.5 mg ranibizumab to 4 mg intravitreal triamcinolone acetonide; when analysis was 
confined to the pseudophakic group of patients to control for the effect of cataract 
formation, the group that received intravitreal triamcinolone acetonide showed similar 
visual acuity results to the group that received ranibizumab.   
In 2014, intravitreal aflibercept was approved for the treatment of DME based on 
Regeneron’s Phase 3 VISTA-DME and VIVID-DME trials.11 Even more recently, 
aflibercept was compared to ranibizumab and bevacizumab for the treatment of DME in 
the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative 
effectiveness study in 660 patients with Diabetic Macular Edema (Protocol T).12 In this 
study, aflibercept demonstrated a significantly greater improvement in mean change in 
BCVA from baseline at 52 weeks compared to both bevacizumab and ranibizumab 
injection, in the subgroups with baseline visual acuity of 20/50 or worse, but there was no 
significant difference in visual acuity between the subgroups with better baseline visual 
acuity (between 20/32 -20/40). Anatomically, aflibercept and ranibizumab demonstrated 
a statistically significant greater reduction of CSFT compared to bevacizumab, with 
values of -169 μm, -147 μm, and -101 μm, respectively. These results held true regardless 
of initial baseline VA, though there was no statistically significant difference in anatomic 
efficacy when comparing ranibizumab to aflibercept. These results suggest that either 
aflibercept or ranibizumab would be of potential benefit for treating persistent DME after 
trial with bevacizumab.    
Despite this growing clinical research data, numerous questions remain.  Most 
clinicians do not follow dosing regimens employed in registration trials, as many will 
follow an off-label “treat and extend” regimen, which has not been studied in large 
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randomized clinical trials. In addition, many clinicians will switch between agents when 
there is suboptimal response, as DME can be refractory to multiple treatment modalities. 
The REEF study (prospective nonrandomized trial of 43 patients) found benefit in 
switching from bevacizumab to three monthly injections of 0.5 mg ranibizumab, with 
mean additional reduction of 113 μm and gain of 6.4 letters by 3 month follow up. As of 
now, there are no large randomized prospective clinical trials comparing treatment 
regimens for refractory DME to guide treatment regimens.   
This study suggests that Ranibizumab can improve DME refractory to some prior 
treatments, including laser photocoagulation, intravitreal triamcinolone acetonide, and 
bevacizumab.  Although the improvement in visual acuity and CSFT is modest, these 
cases can be especially difficult to treat, and consequently these modest improvements 
can be clinically meaningful, especially in patients with bilateral refractory DME. This 
study has several limitations, including its retrospective design without a standardized 
refraction protocol, lack of controls, and lack of long-term follow up. Also, tachyphylaxis 
may be a confounder, that the benefit sometimes observed from simply switching from 
one therapy to another may represent a limitation of this study, potentially accounting for 
the modest benefit observed. In addition, there was a mean wash out period of 167 days 
(range 29 – 455 days) between prior therapy and initiation of ranibizumab, and it is 
possible that the absence of recent therapy contributed to the modest improvement in 
DME. Furthermore, as another limitation of this retrospective study, the average 
treatment frequency of ranibizumab was less than the recommended monthly treatment 
frequency; more frequent monthly treatment would have likely shown a more robust 
improvement in DME after switching to ranibizumab. The mechanism by which 
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ranibizumab may exert more complete effect over the other treatments is unclear, but 
anti-VEGF agents have been shown to have different efficacies in treatment-naïve DME 
with poor baseline visual acuity, as noted above.  Furthermore, given the result of 
DRCR.net protocol T, it is possible that switching therapy to aflibercept could provide 
even more benefit in cases of refractory DME.12 Bevacizumab, ranibizumab, and 
aflibercept each have different binding affinities for VEGF, as well as different half-lives 
in the vitreous, and this could account for some of the differences noted between these 
agents. 
Truly chronic DME may differ even more in pathophysiology from non-chronic 
DME.  A recent study compared the efficacy of a fluocinolone sustained release implant 
in chronic (>/= 3 years) versus nonchronic (<3 years) DME in a preplanned subgroup 
analysis of a large prospective randomized trial.13 At month 36, the difference between 
fluocinolone implant and sham control in the percentage of subjects who gained 15 letters 
or more was significantly greater in 536 chronic DME subjects (34.0% vs. sham, 13.4%; 
P<0.001), compared to the 416 subjects with nonchronic DME (22.3% vs. sham, 27.8%; 
P = 0.275). The differences could not be explained by baseline ocular characteristics, 
changes in anatomic features, or differences in re-treatment or ancillary therapies. The 
authors speculate that early DME is driven primarily by VEGF, while chronic DME may 
be driven more by inflammatory cytokines in addition to anatomic changes, and that 
intravitreal corticosteroids will inhibit the release of these inflammatory cytokines. 
Currently, the DRCR Protocol U is exploring the efficacy of combination therapy 
with 0.3 mg ranibizumab and dexamethasone intravitreal implant compared to continued 
therapy with 0.3 mg ranibizumab to treat persistent DME. Our results, along with those 
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of DRCR Protocol T, suggest the need for large prospective randomized trials to validate 
that switching from either bevacizumab to ranibizumab or aflibercept is superior to 
continued bevacizumab treatment in cases of persistent DME. Clearly, further study of 
refractory DME is warranted, given the visual disability caused. 
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Figure Legends 
 
Figure 1. Mean central subfield thickness (CSFT) in relation to number of days of 
follow up in eyes treated with 0.3 mg intravitreal ranibizumab for refractory diabetic 
macular edema. 
Figure 2. Mean central subfield thickness (CSFT) in relation to number of 0.3 mg 
intravitreal ranibizumab injections in eyes treated for refractory diabetic macular edema  
 Figure 3. Mean logMAR visual acuity (VA) in relation to number of days of 
follow up in eyes treated with 0.3 mg intravitreal ranibizumab for refractory diabetic 
macular edema. 
Figure 4. Mean logMAR visual acuity (VA) in relation to number of 0.3 mg 
intravitreal ranibizumab injections in eyes treated for refractory diabetic macular edema  
 
 
 
 
 
